Skip to content

A multicenter randomized controlled trial of individualized combined serial therapy in the treatment of patients with squamous carcinoma of oromaxillo-facial region i

A study of prevention and treatment of major diseases in otorhinolaryngology, stomatology and ophthalmology

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-07000025
Enrollment
Unknown
Registered
2007-11-10
Start date
2007-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Squamous carcinoma of oromaxillo-facial region in intermediate and advanced stage

Interventions

Control group:Surgery + reconstruction + post-op radiation
Intervention group:Pre-op induction chemotherapy + surgery + reconstruction + post-op radiation

Sponsors

Ninth People's Hospital of Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. 20 to 80 years old; 2. both female and male patients; 3. patients with pathology diagnosis as squamous carcinoma during their first hospital visit; 4. tumor lesion located in tongue, mouth floor, gum, buccal mucosa, palate etc.; 5. TNM status as T2N1M0, T3-4N0-3M0; 6. clinically as III, IV stage; 7. general status capable of tolerating the planned management, no contraindication for surgery, and distant metastasis excluded by scans.

Exclusion criteria

Exclusion criteria: 1. unwilling to receive surgery, making the treatment process impossible and could instead adopt conservative treatment; 2. poor general status making planned therapy intolerable, and conservative treatment better; 3. M1 patients with distant metastasis; 4. T1 patients being in the early clinical stage; 5. T2cN0 patients being in the early clinical stage; 6. T4 patients being inoperable.

Design outcomes

Primary

MeasureTime frame
Survival rate;

Secondary

MeasureTime frame
tumor recurrent rate;

Countries

China

Contacts

Public ContactZhiyuan Zhang
zhang.z.y@hotmail.com+86 0 13701638070

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026